Patents Assigned to Nihon Medi-Physics Co., Ltd.
  • Publication number: 20100249407
    Abstract: The invention relates to a compound which has affinity with amyloid, shows sufficiently rapid clearance from normal tissues and is suppressed in toxicity such as mutagenicity, and also relates to a low-toxic diagnostic agent for Alzheimer's disease containing the compound. The compound is represented by the following formula (1) or a salt thereof: wherein A1, A2, A3 and A4 independently represent a carbon or a nitrogen, and R3 is a group represented by the following formula: wherein R1 is a radioactive halogen substituent; m is an integer of 0 to 4; and n is an integer of 0 or 1, provided that at least one of A1, A2, A3 and A4 represents a carbon, and R3 binds to a carbon represented by A1, A2, A3 or A4.
    Type: Application
    Filed: April 26, 2007
    Publication date: September 30, 2010
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Shigeyuki Tanifuji, Daisaku Nakamura, Shinya Takasaki
  • Publication number: 20100249419
    Abstract: The invention provides a reagent for detecting amyloid deposited in a biological tissue which can detect amyloid in vitro and in vivo with high sensitivity using a compound which has affinity with amyloid and is suppressed in toxicity such as mutagencity. The reagent for detecting amyloid deposited in a biological tissue comprises a compound represented by the following formula (1) or a salt thereof: wherein A1, A2, A3 and A4 independently represent a carbon or nitrogen; R1 is a radioactive halogen substituent; R2 is a group selected from the group consisting of hydrogen, hydroxyl group, methoxy group, carboxyl group, amino group, N-methylamino group, N,N-dimethylamino group and cyano group; and m is an integer of 0 to 2, provided that at least one of A1, A2, A3 and A4 represents a carbon, and R1 binds to a carbon represented by A1, A2, A3 and A4.
    Type: Application
    Filed: October 28, 2008
    Publication date: September 30, 2010
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Shigeyuki Tanifuji, Daisaku Nakamura, Shinya Takasaki, Yuki Okumura
  • Publication number: 20100249418
    Abstract: A compound effective as a probe targeting amyloid for image diagnosis and a reagent comprising the compound for detecting amyloid deposited on a biological tissue are provided. Provided are a compound represented by the following formula (1): wherein R1 is a group selected from the group consisting of a halogen substituent, alkyl substituent with 1 to 4 carbon atoms, alkoxy substituent having alkyl chain with 1 to 4 carbon atoms and hydroxyl group, R2 is a group selected from the group consisting of a cyano substituent, alkyl substituent with 1 to 4 carbon atoms and halogen substituent, R3 is a group selected from the group consisting of a hydroxyl group, halogen substituent and substituent represented by the following formula: (wherein R4 is a hydrogen, halogen substituent or hydroxyl group, and m is an integer of 1 to 4), provided that at least one of R1, R2, R3 and R4 represents a radioactive halogen, and a reagent comprising the same.
    Type: Application
    Filed: October 24, 2008
    Publication date: September 30, 2010
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Shigeyuki Tanifuji, Daisaku Nakamura, Shinya Takasaki, Yuki Okumura
  • Publication number: 20100249408
    Abstract: The invention provides a reagent for detecting amyloid in a biological tissue which can detect amyloid in vitro and in vivo with high sensitivity using a compound which has affinity with amyloid and is suppressed in toxicity such as mutagenicity. The reagent for detecting amyloid deposited in a biological tissue comprises the compound represented by the following formula (1) or a salt thereof: wherein A1, A2, A3 and A4 independently represent a carbon or a nitrogen, and R3 is a group represented by the following formula: wherein R1 is a radioactive halogen substituent; m is an integer of 0 to 4; and n is an integer of 0 or 1, provided that at least one of A1, A2, A3 and A4 represents a carbon, and R3 binds to a carbon represented by A1, A2, A3 or A4.
    Type: Application
    Filed: October 28, 2008
    Publication date: September 30, 2010
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Shigeyuki Tanifuji, Daisaku Nakamura, Shinya Takasaki, Yuki Okumura
  • Publication number: 20100216994
    Abstract: The invention provides a reagent which can detect amyloid in vitro and in vivo with high sensitivity using a compound which has affinity with amyloid. The reagent for detecting amyloid deposited in a biological tissue comprises the compound represented by the following formula (1) or a salt thereof: wherein A1, A2, A3 and A4 independently represent a carbon or nitrogen, R2 is a group selected from the group consisting of a hydrogen, hydroxyl group, carboxyl group, sulfuric acid group, amino group, nitro group, cyano group, non-radioactive halogen substituent, alkyl substituent with 1 to 4 carbon atoms and alkoxy substituent with 1 to 4 carbon atoms, and R2 is a radioactive halogen substituent, provided that at least one of A1, A2, A3 and A4 represents a carbon, and R1 binds to a carbon represented by A1, A2, A3 or A4.
    Type: Application
    Filed: October 28, 2008
    Publication date: August 26, 2010
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Shigeyuki Tanifuji, Daisaku Nakamura, Shinya Takasaki, Yuki Okumura
  • Publication number: 20100092387
    Abstract: A compound that has affinity with amyloid, exhibits sufficiently rapid clearance from normal tissues, and is suppressed in toxicity such as mutagenicity is provided, which is represented by the following formula (1): or a salt thereof, wherein R1 is a group selected from hydrogen, hydroxyl group, carboxyl group, sulfate group, amino group, nitro group, cyano group, an alkyl substituent with one to 4 carbon atoms or an alkoxy substituent with one to 4 carbon atoms; R2 is a radioactive halogen substituent; and m is an integer of 0 to 2, and a low-toxic diagnostic agent for Alzheimer's disease comprising a compound represented by the above formula or a salt thereof is also provided.
    Type: Application
    Filed: June 21, 2007
    Publication date: April 15, 2010
    Applicants: NIHON MEDI-PHYSICS CO., LTD., GE HEALTHCARE LIMITED
    Inventors: Shigeyuki Tanifuji, Akio Hayashi, Daisaku Nakamura, Shinya Takasaki, Storey Anthony Eamon, Denis Raymond Christophe Bouvet
  • Publication number: 20100074480
    Abstract: CPU 12 reads out the bloodstream associated values of target voxel of subject's standardized brain bloodstream images (step S34). CPU 12 sorts the bloodstream associated values in descending order (step S35). CPU 12 rejects bloodstream associated values that are ranked top 10% and bottom 40% (step S36). When the subjects are 20 for example, bloodstream associated values of highest 2 subjects and of lowest 8 subjects are rejected. CPU 12 calculates and stores mean value and standard deviation of remaining bloodstream associated values after the rejection (step S37). CPU 12 calculates mean value and standard deviation of bloodstream associated values for each voxel as target voxel (steps S31, S32, S33 and S38). Then, the alternative normal brain database of brain bloodstream image is obtained.
    Type: Application
    Filed: September 22, 2008
    Publication date: March 25, 2010
    Applicants: UNIVERSITY OF WASHINGTON, NIHON MEDI-PHYSICS CO., LTD
    Inventors: Satoshi Minoshima, Kiyotaka Watanabe, Shuya Miki, Kazuhiro Nishikawa
  • Publication number: 20100028258
    Abstract: A composition including a radioactive fluorine-labeled amino acid compound is provided, which can be prevented from radiolysis. Disclosed is a composition which includes a solution containing a radioactive fluorine-labeled amino acid compound as an effective ingredient, in which the pH value of the solution is kept at 2.0-5.9, more preferably 2.0-4.9 in order to inhibit radiolysis. Also, it is possible to further inhibit radiolysis by adding thereto a pharmaceutical additive capable of inhibiting radiolysis, such as a sugar, a sugar alcohol and a sugar lactone, whilst the pH is kept at 2.0-5.9.
    Type: Application
    Filed: November 20, 2007
    Publication date: February 4, 2010
    Applicant: Nihon Medi-Physics Co., Ltd.
    Inventors: Akio Hayashi, Toshiyuki Shinmura, Daisaku Nakamura, Soichi Takasaki, Shinji Tokunaga, Emi Kaneko, Masahito Toyama
  • Publication number: 20100016626
    Abstract: A process is provided for producing a labeled precursor which is useful for production of a radioactive fluorine-labeled amino acid compound. In the reaction step for introducing a leaving group to a mixture of syn-form and anti-form of FACBC, a base is allowed to present in the reaction system to produce a syn-leaving group adduct, which is unreactive with the base and is highly stable, and an anti-leaving group adduct which can react with the base to form a water-soluble compound. By employing a purification method utilizing such a difference in solubility, the syn-leaving group adduct can be separated selectively. The base may be a linear- or branched-chain primary to tertiary alkylamine having 1 to 10 carbon atoms, a nitrogen-containing heterocyclic compound with 2 to 20 carbon atoms, and a nitrogen-containing hetero aromatic compound with 2 to 20 carbon atoms.
    Type: Application
    Filed: December 17, 2007
    Publication date: January 21, 2010
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Masahito Toyama, Akio Hayashi
  • Publication number: 20090290765
    Abstract: A method of detecting a neurodegenerative disease includes (a) a standardization step of creating a first image by applying anatomical standardization to a brain nuclear medical image; (b) a conversion step of creating a second image by converting the pixel value of each pixel of an image based on the first image into a z score or a t value; (c) an addition step of calculating the sum of the pixel values of individual pixels in a predetermined region of interest in the second image; and (d) a detection step of obtaining the results of the detection of the neurodegenerative disease through an operation of comparison of the sum with a predetermined threshold.
    Type: Application
    Filed: October 24, 2006
    Publication date: November 26, 2009
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Kazunari Ishii, Kiyotaka Watanabe, Shuya Miki, Kazuo Hamada
  • Publication number: 20090281294
    Abstract: A process for the production of [18F]-TAFDG can produce [18F]-TAFDG in a high radiofluorination yield. A process for the production of an organic compound labeled with radioactive fluorine includes the steps of preparing a reaction solution containing [18F]fluoride ions, a phase transfer catalyst, potassium ions, 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-?-D-mannopyranose as a labeling precursor compound and a solvent, and giving a reaction condition to the reaction solution to obtain 1,3,4,6-tetra-O-acetyl-2-[18F]fluoro-2-deoxyglucose, in which the solvent contains water.
    Type: Application
    Filed: November 30, 2006
    Publication date: November 12, 2009
    Applicant: Nihon Medi-Physics Co., Ltd.
    Inventors: Keiichi Hirano, Daisaku Nakamura
  • Publication number: 20090252680
    Abstract: A compound represented by the following formula or a salt thereof: wherein each of A1, A2, A3 and A4 independently represents a carbon or nitrogen; R1 is a group selected from the group consisting of hydrogen, hydroxyl group, carboxyl group, sulfuric acid group, amino group, nitro group, cyano group, non-radioactive halogen substituents, alkyl substituents with 1-4 carbon atoms and alkoxy substituents with 1-4 carbon atoms; and R2 is a radioactive halogen substituent, provided at least one of A1, A2, A3 and A4 represents a carbon, and R1 binds to a carbon represented by A1, A2, A3 or A4, is effective as an image diagnosis probe targeting amyloid and as well as a diagnostic agent for Alzheimer's disease including the compound represented by the above formula or a salt thereof.
    Type: Application
    Filed: October 30, 2007
    Publication date: October 8, 2009
    Applicant: NIHON- MEDI-PHYSICS CO., LTD
    Inventors: Shigeyuki Tanifuji, Daisaku Nakamura, Shinya Takasaki, Yuki Okumura
  • Publication number: 20090252679
    Abstract: The present invention provides a compound which has affinity with amyloid, shows sufficiently rapid clearance from normal tissues and is suppressed in toxicity such as mutagencity. Provided is a compound represented by the following formula (1) or a salt thereof: wherein A1, A2, A3 and A4 independently represents a carbon or nitrogen; R1 is a halogen substituent; R2 is a halogen substituent; and m is an integer of 0 to 2, provided that at least one of R1 and R2 is a radioactive halogen substituent, at least one of A1, A2, A3 and A4 represents a carbon, and R1 binds to a carbon represented by A1, A2, A3 or A4 as well as a low-toxic diagnostic agent comprising a compound represented by the preceding formula or a salt thereof.
    Type: Application
    Filed: May 15, 2007
    Publication date: October 8, 2009
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Shigeyuki Tanifuji, Daisaku Nakamura, Shinya Takasaki, Yuki Okumura
  • Publication number: 20090198085
    Abstract: A process is provided for producing [18F]FACBC, which can reduce the production amount of impurities.
    Type: Application
    Filed: May 7, 2007
    Publication date: August 6, 2009
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Emi Kaneko
  • Publication number: 20090148019
    Abstract: An image processing method is provided as one for creating a fused image automatically and with high overlapping accuracy. An image processing method according to an embodiment of the present invention includes (a) a voxel normalization step of equalizing voxel sizes and numbers of voxels in respective effective fields of view of a first 3D image based on a plurality of first tomographic images obtained from an arbitrary part of a subject and a second 3D image based on a plurality of second tomographic images obtained from the same part, thereby creating a first normalized 3D image corresponding to the first 3D image and a second normalized 3D image corresponding to the second 3D image; and (b) a fused image creation step of creating a fused image, using the first normalized 3D image and the second normalized 3D image.
    Type: Application
    Filed: February 21, 2006
    Publication date: June 11, 2009
    Applicant: Nihon Medi-Physics Co., Ltd.
    Inventors: Kazuo Hamada, Kazuhiro Nishikawa
  • Publication number: 20090105489
    Abstract: It is intended to provide a labeling precursor compound used for selectively producing radioactive halogen-substituted syn-1-amino-3-cyclobutane-carboxylic acids, and to provide a process for producing a radioactive halogen-substituted syn-1-amino-3-cyclobutane-carboxylic acid using the labeling precursor compound. A labeling precursor is used in which a phthalimide group is used as a protective group for protecting the amino group. The syn-form of the radioactive halogen-substituted 1-amino-3-cyclobutane-carboxylic acid can be selectively produced by labeling the labeling precursor with a radioactive halogen followed by deprotecting.
    Type: Application
    Filed: May 15, 2006
    Publication date: April 23, 2009
    Applicant: NIHON MEDI-PHYSICS CO. LTD.
    Inventors: Masahito Toyama, Fumie Kurosaki, Akio Hayashi, Osamu Ito
  • Publication number: 20090030192
    Abstract: A process for the production of [18F]fluoro-2-deoxyglucose can produce [18F]fluoro-2-deoxyglucose in a high and stable yield of synthesis. A process for the production of a compound labeled with radioactive fluorine includes the preparing a reaction solution by adding, under a hermetic condition, TATM and an inert organic solvent to a mixture containing [18F]fluoride ions, a phase transfer catalyst and potassium ions, giving a reaction condition to the reaction solution under a hermetic condition to obtain [18F]-TAFDG, and subjecting the obtained [18F]fluoro-2-deoxyglucose to a deprotection process and, optionally, to a purification process to obtain [18F]fluoro-2-deoxyglucose.
    Type: Application
    Filed: November 30, 2006
    Publication date: January 29, 2009
    Applicant: Nihon Medi-Physics Co., Ltd.
    Inventors: Keiichi Hirano, Daisaku Nakamura
  • Publication number: 20080281121
    Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.
    Type: Application
    Filed: November 28, 2006
    Publication date: November 13, 2008
    Applicant: NIHON MEDI-PHYSICS CO., LTD.
    Inventors: Osamu Ito, Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Arinori Harano
  • Patent number: 7445765
    Abstract: A radiopharmaceutical for diagnostic imaging containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound as a ? electron acceptor and a bidentate ligand as a ? electron donor and represented by the following formula (I): [99mTc(N)(PNP)(XY)]+ (I)wherein 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand, is markedly accumulated in heart and adrenal glands and hence is useful for radiodiagnostic imaging of heart and adrenal glands.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: November 4, 2008
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Alessandra Boschi, Fiorenzo Refosco, Francesco Tisato
  • Publication number: 20080267868
    Abstract: A process for diagnostic imaging of heart or adrenal glands of a human being comprises administering to the human being a radiopharmaceutical containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound and a bidentate ligand and represented by the formula (1): [99mTc(N)(PNP)(XY)]+. In this formula, 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand as described in the specification. The compound of the formula is markedly accumulated in heart and adrenal glands and hence is used for radiodiagnostic imaging of heart and adrenal glands.
    Type: Application
    Filed: August 9, 2007
    Publication date: October 30, 2008
    Applicant: Nihon Medi-Physics, Co., Ltd.
    Inventors: Adriano Duatti, Cristina Bolzati, Licia Uccelli, Alessandra Boschi, Fiorenzo Refosco, Francesco Tisato